Abstract：
Background: This study investigated the influence of ADRB1 gene rs1801253 polymorphism on the treatment response of ticagrelor and aspirin in patients with acute coronary syndrome (ACS). Methods: Genetic typing was detected by Sanger sequencing. Platelet inhibition was assessed using thromboelastography. Kaplan-Meier and Cox regression were applied for prognosis analysis. Results: Out of 200 participants, 94 cases with rs1801253-CC genotype and 106 cases with CG+GG genotype were found. There was no significant difference between the rs1801253-CC and CG+GG groups in the number of ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction and unstable angina patients. There was no statistical difference in the basic data of patients in the two groups in terms of age, sex, medical history and medicine use in the dominant model. The rs1801253-CC genotype was a risk prognostic factor for ACS patients based on the Cox regression analysis results. Conclusion: Detecting ADRB1 polymorphism is crucial for ACS patients undergoing treatment with ticagrelor and aspirin.
[Box: see text].
[Box: see text].
摘要：
背景：本研究调查了ADRB1基因rs1801253多态性对急性冠脉综合征（ACS）患者替格瑞洛和阿司匹林治疗反应的影响。方法:采用Sanger测序法进行基因分型检测。使用血栓弹力图评估血小板抑制。采用Kaplan-Meier和Cox回归进行预后分析。结果：在200名参与者中，发现94例rs1801253-CC基因型和106例CGGG基因型。rs1801253-CC组和CG+GG组的ST段抬高型心肌梗死数量差异无统计学意义,非ST段抬高型心肌梗死和不稳定型心绞痛患者。两组患者的基本资料在年龄方面无统计学差异,性别,病史和药物在主导模式中的使用。根据Cox回归分析结果，rs1801253-CC基因型是ACS患者的危险预后因素。结论：检测ADRB1基因多态性对接受替格瑞洛和阿司匹林治疗的ACS患者至关重要。
